– CANADA, Montreal – Theratechnologies Inc. (TSX: TH | NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Andrew Molson and Alain Trudeau to its Board as Independent Directors.
“Both Andrew and Alain bring tremendous value to our Board. They are well-recognized and respected by their peers in the business community for their knowledge, expertise and vision,” said Board Chair, Dawn Svoronos.
She added: “On behalf of the Board of Directors at Theratechnologies, it is my pleasure to welcome them. We look forward to the important contribution Andrew and Alain will make as Theratechnologies enters a new chapter in its history. Theratechnologies recently announced its intent to develop tesamorelin for the treatment of Nonalcoholic Steatohepatitis in the general population while it continues to advance its SORT1+ Technology platform in oncology. These programs, along with the commercialization of EGRIFTA SV and Trogarzo, position Theratechnologies to become a much larger player in the pharmaceutical industry.”
About Andrew Molson
Andrew Molson serves as chairman of AVENIR GLOBAL, an organization uniting seven strategic communications firms across Canada, the U.S., Europe, and the Middle East. He is also chairman of Molson Coors Beverage Company and a member of the board of directors of Groupe Deschênes Inc., Dundee Corporation, and the CH Group Limited Partnership, owner of evenko and the Montreal Canadiens.
He previously served as a director of The Group Jean Coutu PJC Inc. from 2014 to 2018, as Chair of Molson Coors from May 2011 to May 2013, and as its Vice-Chair from May 2009 to May 2011.
He was called to the Quebec Bar in 1995 after studying law at Laval University in Quebec City. He also holds a Bachelor of Arts from Princeton University and a Master of Science in corporate governance and ethics from the University of London (Birkbeck College). Mr. Molson serves on several non-profit boards, including the Institute for Governance of Private and Public Organizations, Concordia University Foundation, the Québec Blue Cross, the evenko foundation for emerging talent, the Montreal General Hospital Foundation, and the Molson Foundation, a family foundation dedicated to the betterment of Canadian society.
About Alain Trudeau
A fellow of the Quebec CPA Order, Alain Trudeau has had a distinguished career at Ernst & Young from 1982 to 2019 where he held the position of Managing Partner, Assurance Services, for EY offices in the Province of Quebec from 2008 to 2019. He was also responsible for the audit of many publicly-traded companies.
He currently serves on the board of directors of the Montréal Inc. Foundation, the Institut de médiation et d’arbitrage du Québec, and Blue Bridge Trust Company Inc.
From 2008 to 2019, Mr. Trudeau was a lecturer at the Collège des administrateurs de sociétés de l’université Laval in Quebec City.
Mr. Trudeau holds a Bachelor of Arts in Accounting from HEC Montréal.
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.
For more information: https://www.theratech.com/en/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.